NCT05733572View on ClinicalTrials.gov

Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)

PHASE2RecruitingINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

June 12, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

April 30, 2026

Conditions

Optic Pathway Glioma

Interventions

DRUG

CHF6467

drug eyedrops

DRUG

Placebo

placebo eyedrops

Trial Locations (1)

00168

RECRUITING

Catholic University, Policlinico A. Gemelli (Hospital), Rome

All Listed Sponsors

lead

Benedetto Falsini

OTHER